Sagimet Biosciences Inc. (NASDAQ: SGMT)
$3.66
+0.2600 ( +7.65% ) 425.5K
Sagimet Biosciences Inc is a clinical-stage biopharmaceutical company focused on developing a portfolio of in-house discovered, selective fatty acid synthase (FASN) inhibitors for the treatment of diseases that result from dysfunctional lipid metabolism pathways. The company's lead drug candidate, denifanstat, is an oral, once-daily pill and selective FASN inhibitor in development for the treatment of nonalcoholic steatohepatitis (NASH).
Market Data
Open
$3.66
Previous close
$3.40
Volume
425.5K
Market cap
$116.49M
Day range
$3.35 - $3.67
52 week range
$2.13 - $20.71
SEC Fillings
Form Type | Description | Pages | Date |
---|---|---|---|
8-k | 8K-related | 15 | May 15, 2024 |
4 | Insider transactions | 1 | May 08, 2024 |
3 | Insider transactions | 2 | May 08, 2024 |
8-k | 8K-related | 13 | May 06, 2024 |
def | Proxies and info statements | 9 | Apr 18, 2024 |
ars | Annual reports | 1 | Apr 18, 2024 |
3 | Insider transactions | 2 | Apr 03, 2024 |
4 | Insider transactions | 1 | Apr 03, 2024 |
3 | Insider transactions | 2 | Apr 03, 2024 |
4 | Insider transactions | 1 | Apr 03, 2024 |